Data Readout

Inventiva's NATiV3 completion date slips 43 months, pushing lanifibranor readout to late 2027

The Phase 3 MASH trial's primary completion date has moved four times since 2023, and the warrant financing tied to topline data now outlives the trial's own registered timeline.

By AppliedXLJuly 13, 2026Trial NCT04849728

Executive Summary

Inventiva's pivotal MASH trial has finished enrolling and moved to a watch-and-wait phase, with the topline readout now the single event standing between the drug and its next development decision.
The trial's own registered completion date has drifted later multiple times and now lands after the deadline a separate financing arrangement uses to trigger warrant exercises, creating a gap between the sponsor's operational commitment and its capital-markets guidance.
The MASH field already has one approved oral treatment, and this trial represents the only late-stage test of the pan-PPAR mechanism in the disease, so a positive result would open a second, mechanistically distinct treatment option rather than displace an established standard.
Enrollment reaching target and the trial's shift to Active, not recruiting status reflect normal Phase 3 progression, not a sign of trouble; the repeated completion-date extensions are the more consequential operational fact.

The trial and the mismatch

NCT04849728, known as NATiV3, is testing lanifibranor, an oral pan-PPAR agonist, against fibrosis and NASH resolution endpoints in roughly 1,000 patients with fibrosis stages F2 and F3. The trial's primary completion date has moved four times in the registry: from February 2024 to September 2025 in April 2023, then to December 2026 in March 2026, then to June 2027 in May 2026, and most recently to September 30, 2027, a change logged May 20, 2026. That last move happened after the company's own structured financing tied warrant exercise to topline data arriving no later than June 15, 2027, a deadline disclosed in May 2025. The trial's registered completion date now falls three and a half months after that financing window closes. NCT04849728+1

What the trial has already shown operationally

Inventiva reported in May 2025 that NATiV3 had completed enrollment, which it cited as satisfying a condition for a $116 million second tranche of financing. Chief Executive Officer Frederic Cren said at the time: "We are pleased to have achieved the timely enrollment of NATiV3 and met all the conditions for the issuance of this second tranche". The trial's status changed to Active, not recruiting in March 2026, consistent with a fully enrolled Phase 3 study now following patients to its primary endpoint rather than continuing to recruit. Enrollment itself was cut from an original target of 2,000 to 1,000 patients in April 2023, a change made more than two years before the current completion-date slippage and unrelated to it. INVENTIVA-INVENTIVA+1

The competitive field

MASH has one FDA-approved oral therapy, resmetirom, a thyroid hormone receptor-beta agonist from Madrigal Pharmaceuticals, whose own late-stage outcomes trial is still active in the same competitive field. Lanifibranor's pan-PPAR mechanism, which activates PPAR-alpha, PPAR-delta and PPAR-gamma together, has no resolved Phase 3 precedent of its own; the nearest mechanism neighbor in active development is Zydus Therapeutics' saroglitazar magnesium, a PPAR-alpha agonist still in Phase 2 for the same indication. Other late-stage MASH programs, including Akero Therapeutics' efruxifermin and 89bio's pegozafermin, work through different mechanisms in the FGF21 pathway and sit in the broader indication landscape rather than as direct comparators.

Regulatory backdrop

Lanifibranor holds FDA Fast Track and Breakthrough Therapy designations for NASH, both granted in 2020, along with Breakthrough Therapy designation from China's NMPA in December 2023. Those designations reflect the FDA's assessment of unmet need in the disease and the drug's earlier Phase 2b data; they do not by themselves indicate how NATiV3 will read out.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.